---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-23-000022"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:46:53.441469+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NovoCure Q4 2022 net revenues $128.4M, full year $537.8M; LUNAR study meets primary endpoint

## Summary
- Full year 2022 net revenues $537.8M (+1% YoY); Q4 net revenues $128.4M (-4% YoY).
- Q4 net loss $37.3M ($0.36 loss per share); adjusted EBITDA $(10.5)M.
- Active patients 3,430 as of Dec 31, 2022 (-4% YoY); prescriptions 1,373 in Q4 (-4% YoY).
- Pivotal LUNAR study in NSCLC met primary overall survival endpoint; PANOVA-3 enrollment completed.
- Elected Dr. Allyson J. Ocean to Board of Directors; CE Mark for new array, limited market release in Europe.

## SEC filing metadata
- accession: 0001645113-23-000022
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000022/0001645113-23-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000022/nvcr-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-23-000022
- JSON: https://secwatch.observer/filing/0001645113-23-000022.json
- Plain text: https://secwatch.observer/filing/0001645113-23-000022.txt

## Key facts
- Earnings Releases
  NovoCure Ltd reported the fourth quarter ended December 31, 2022 results: revenue $128.4 million, net income $37.3 million, EPS $0.36 per share.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $128.4 million
  - Net income: $37.3 million
  - EPS: $0.36 per share
  - Result: reported results
  source text: Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update Full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million Pivotal LUNAR study in non-small cell lung cancer met primary overall survival endpoint and a key secondary overall survival endpoint Novocure completes enrollment of the pivotal
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000022/0001645113-23-000022-index.htm
- Earnings Releases
  NovoCure Ltd reported the fiscal year ended December 31, 2022 results: revenue $537.8 million.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $537.8 million
  - Result: reported results
  source text: Total net revenues for the year were $537.8 million, an increase of 1% year-over-year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000022/0001645113-23-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.